MGNX Stock Price
MacroGenics, Inc.
MGNX stock price is $3.31 (-3.22% on the day), giving MacroGenics, Inc. a market cap of $210.85M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
MGNX Stock Overview
- Price
- $3.31
- Previous close
- $3.42
- Open
- $3.42
- Market cap
- $210.85M
- P/E ratio
- -2.8
- 52-week range
- $1.29 - $5.08
- 1-year price target
- $8.00
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 38
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MGNX | $3.31 | -3.2% | 906.74K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |